Journal
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
Volume 66, Issue 10, Pages 932-943Publisher
OXFORD UNIV PRESS INC
DOI: 10.1097/nen.0b013e3181567d59
Keywords
annexin A1; inflammation; neuroprotection; phospholipase A(2); spinal cord injury
Categories
Funding
- NCRR NIH HHS [RR15576] Funding Source: Medline
- NINDS NIH HHS [NS36350, NS52290] Funding Source: Medline
Ask authors/readers for more resources
Annexin A1 (ANYA1) has been suggested to be a mediator of the anti-inflammatory actions of glucocorticoids and more recently an endogenous neuroprotective agent. In the present study, we investigated the anti-inflammatory and neuroprotective effects of ANXA1 in a model of contusive spinal cord injury (SCI). Here we report that injections of ANXA1 (Ac 2-26) into the acutely injured spinal cord at 2 concentrations (5 and 20 mu g) inhibited SCI-induced increases in phospholipase A(2) and myeloperoxidase activities. In addition, ANXA1 administration reduced the expression of interleukin-1 beta and activated caspase-3 at 24 hours, and glial fibrillary acidic protein at 4 weeks postinjury. Furthermore, ANXA1 administration significantly reversed phospholipase A(2)-induced spinal cord neuronal death in vitro and reduced tissue damage and increased white matter sparing in vivo, compared to the vehicle-treated controls. Fluorogold retrograde tracing showed that ANXA1 administration protected axons of long descending pathways at 6 weeks post-SCI. ANXA1 administration also significantly increased the number of animals that responded to transcranial magnetic motor-evoked potentials. However, no measurable behavioral improvement was found after these treatments. These results, particularly the improvements obtained in tissue sparing and electrophysiologic measures, suggest a neuroprotective effect of ANXA1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available